Experts explain the science behind a 21-year study that followed over 100,000 women.

NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone ...

More than 795,000 people in the U.S. have a stroke each year, which is a leading cause of serious long-term disability. Many of the leading risk factors for stroke are modifiable, making prevention ...

The 2026 International Stroke Conference (ISC), held February 4-6 in New Orleans, Louisiana, delivered potentially ...

The results showed that women who followed the Mediterranean diet most closely had significantly lower stroke risk across the board. Those with the highest Mediterranean diet scores (6-9 out of 9) had ...

New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care equitably with smart wearables. The future of stroke care is likely to be ...

A long-term study found that women who closely followed a Mediterranean diet had a much lower risk of stroke. The strongest benefits were seen in women who ate more plant-based foods, fish, and olive ...

The American Heart Association released a scientific statement on preventing and treating maternal stroke during pregnancy and postpartum.

Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

Asundexian significantly reduced the risk of recurrent stroke vs placebo when added to antiplatelet therapy. Topline results were announced from a phase 3 trial evaluating asundexian, an ...

Many people who experience a transient ischemic attack will go on to have a stroke within 90 days. Here are the red flags.

Factor XIa inhibitor milvexian did not provide meaningful secondary prevention over dual antiplatelet therapy for stroke survivors, the phase II trial AXIOMATIC-SSP found. In patients with recent ...